Loading...
•
Dec 31, 2019
Lineage Q4 2019 Earnings Report
Reported financial and operating results for the fourth quarter and full year ended December 31, 2019.
Key Takeaways
Lineage Cell Therapeutics reported Q4 2019 revenues of $1.2 million, an increase of $0.4 million compared to 2018. The net loss attributable to Lineage for the quarter was $4.5 million, or $0.03 per share, compared to a net loss of $45.0 million, or $0.35 per share, for the same period in 2018.
Established Lineage as a leading cell therapy company.
Expanded clinical pipeline by combining three complementary cell therapy assets.
Significantly reduced cash burn by eliminating non-core activities.
Focused priorities and rebranded the company with a new leadership team, name, and headquarters in San Diego County.
Revenue by Segment
Forward Guidance
Lineage anticipates that net operational spend for 2020 will be approximately $16 million. Assuming the Juvenescence note is paid in cash at maturity, the Company believes that it is funded well into 2021 as a result of these cost savings initiatives.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...